Background Beta‐blocker therapy has a proven mortality benefit in patients with
hypertension, heart failure and coronary artery disease, as well as during the perioperative …

Labetalol is a combined alpha‐and beta‐adenoceptor blocking agent for oral and
intravenous use in the treatment of hypertension. It is a nonselective competitive antagonist …

Although verapamil is a well-established treatment for angina, cardiac arrhythmias and
cardiomyopathies, this review reflects current interest in calcium antagonists as …

We present a two-part review of the English-language literature pertaining to drug therapy
for systemic high BP in patients with pulmonary diseases. Part I examines the literature …

Background There is conflicting information regarding the effects of selective and
nonselective beta-blocker treatment in patients with COPD. Participants and methods This …

We compared verapamil and propranolol hydrochloride for monotherapy of hypertension.
Verapamil lowered blood pressure (BP) more effectively than propranolol in black and white …

Calcium channel blockers (CCB) have had a major impact in the treatment of patients with
ischemic heart disease and a variety of cardiovascular and noncardiovascular disorders …

Since labetalol was first reviewed in the Journal (1978), its scope of therapeutic use has
expanded and become better defined. Labetalol is an adrenoceptor blocking drug with …

The proper drug choice determines the treatment quality for a disease. The
pharmacotherapeutic strategy for respiratory diseases often involves the combination of …

When a patient with chronic obstructive pulmonary disease (COPD) requires medical
therapy for systemic hypertension, a number of special considerations may affect the choice …